Maze Therapeutics' stock surged 5.65% during Tuesday's intraday trading session, reflecting strong investor interest in the biopharmaceutical company.
The price movement follows a series of positive analyst actions. Mizuho Securities maintained a Buy rating on the company with a price target of $97.00. Additionally, J.P. Morgan raised its price target for Maze Therapeutics to $58 from $52 and reiterated its Buy rating on the stock.
Investor attention may also be focused on the company's upcoming first-quarter earnings report, which is scheduled to be released in the week ahead according to market calendars.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments